It often takes 10 to 15 years for the industry associated with a new agricultural crop to mature. While it is true that foreign imports have been the basis for hemp products in North America for at least a decade, North American production is only 4 years of age in Canada, and farming of hemp in the US has not even begun. Viewed from this perspective, the hemp industry in North America is still very much in its infancy. Varieties of hemp specifically suited to given products and regions have only started to be developed in North America. There is considerable uncertainty regarding yields, costs of production, harvesting and processing equipment, product characteristics, foreign competition, governmental support, and the vagaries of the regulatory environment. Hemp is not presently a standard crop, and is likely to continue experiencing the risks inherent in a small niche market for some time. Hemp is currently a most uncertain crop, but has such a diversity of possible uses, is being promoted by extremely enthusiastic market developers, and attracts so much attention that it is likely to carve out a much larger share of the North American marketplace than its detractors are willing to concede.
Nabiximols (Sativex), a Cannabis extract with a 1:1 ratio of THC:CBD, is approved in Canada (under the Notice of Compliance with Conditions) for symptomatic relief of pain in advanced cancer and multiple sclerosis. Canada, New Zealand, and some countries in Europe also approve nabiximols for spasticity of multiple sclerosis, a common symptom that may include muscle stiffness, reduced mobility, and pain, and for which existing therapy is unsatisfactory.
Three controlled trials demonstrated that oral THC has variable effects on appetite stimulation and weight loss in patients with advanced malignancies and human immunodeficiency virus (HIV) infection. One study evaluated the efficacy of dronabinol alone or with megestrol acetate compared with that of megestrol acetate alone for managing cancer-associated anorexia. In this randomized, double-blind study of 469 adults with advanced cancer and weight loss, patients received 2.5 mg of oral THC twice daily, 800 mg of oral megestrol daily, or both. Appetite increased by 75% in the megestrol group and weight increased by 11%, compared with a 49% increase in appetite and a 3% increase in weight in the oral THC group after 8 to 11 weeks of treatment. These two differences were statistically significant. Furthermore, the combined therapy did not offer additional benefits beyond those provided by megestrol acetate alone. The authors concluded that dronabinol did little to promote appetite or weight gain in advanced cancer patients compared with megestrol acetate. However, a smaller, placebo-controlled trial of dronabinol in cancer patients demonstrated improved and enhanced chemosensory perception in the cannabinoid group—food tasted better, appetite increased, and the proportion of calories consumed as protein was greater than in the placebo recipients.
Rather than keeping people out of the industry, Money thinks regulators should focus on helping farmers sell their products: for example, by connecting them with the "biomass brokers" who deal in the fibers, stalks, and seed matter produced by industrial hemp. "What I'm finding is that a lot of farmers in Wisconsin don't know what to do with their products," she said. "We tried to get a list of licensed farmers to help connect them with brokers, but the state wouldn't release that list."
Understanding the mechanism of cannabinoid-induced analgesia has been increased through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists. Cannabinoids produce analgesia through supraspinal, spinal, and peripheral modes of action, acting on both ascending and descending pain pathways. The CB1 receptor is found in both the central nervous system (CNS) and in peripheral nerve terminals. Similar to opioid receptors, increased levels of the CB1 receptor are found in regions of the brain that regulate nociceptive processing. CB2 receptors, located predominantly in peripheral tissue, exist at very low levels in the CNS. With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.[43,44]
Canabidol™ Oral Capsules deliver 100% Cannabis Sativa L. from specifically bred industrial hemp plants containing high potency Cannabidiol. Each CBD capsule contains all the Cannabinoids, terpenoids, essential oils and all the other compounds of the cannabis plant. A packet of 30 capsules contains 15,000mg of Cannabis Sativa L. and 300mg of CBD (Cannabidiol) Each capsule contains 500mg of Cannabis Sativa L. and 10mg of the active ingredient CBD
My husband was diagnosed with ALS (amyotrophic lateral sclerosis) when he was 61 years old 4 years ago. The Rilutek (riluzole) did very little to help him. The medical team did even less. His decline was rapid and devastating. His arms weakened first, then his hands and legs. Last year, a family friend told us about Rich Herbs Foundation (RHF) and their successful ALS TREATMENT, we visited their website www. richherbsfoundation. com and ordered their ALS/MND Formula, i am happy to report the treatment effectively treated and reversed his Amyotrophic Lateral Sclerosis (ALS), most of the symptoms stopped, he is able to walk and able to ride his treadmill again, he is pretty active now.
Cannabis research suggests medical marijuana could become an effective treatment for diabetic neuropathy. Diabetic neuropathy is a debilitating and sometimes fatal condition caused by diabetes. Diabetics suffer from high blood sugar due to insulin resistance, and this damages nerve cells in the body, causing severe pain. Patients who consumed THC as part of a study found they experienced less pain. Findings are not definitive, however, and further research into cannabis as a treatment for diabetes and associated symptoms is required.
No ongoing clinical trials of Cannabis as a treatment for cancer in humans were identified in a PubMed search. The only published trial of any cannabinoid in patients with cancer is a small pilot study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma multiforme, which demonstrated no significant clinical benefit.[19,20] In a trial (NCT02255292) conducted in Israel, oral cannabidiol (CBD) was investigated as a single salvage agent for recurrent solid tumors. The study was projected to be completed in 2015; however, no results have been published. A small exploratory phase II study (GWCA1208 Part A [NCT01812603]) was conducted in the United Kingdom that used nabiximols, a 1:1 ratio of THC:CBD in a Cannabis-based medicinal extract oromucosal spray, in conjunction with temozolomide in treating patients with recurrent glioblastoma multiforme. The study enrolled 21 patients. Final results have not been published.
A rather thorough analysis of the scope of the illicit marijuana industry in Canada for 1998 is reported at www.rcmp-grc.gc.ca/html/drugsituation.htm#Marihuana and summarized in MacLeod (1999). At least 800 tonnes (t) of marijuana were grown in Canada in 1998, representing a harvest of 4.7 million flowering plants. More than 50% of the marijuana available in Canada is grown domestically. An average mature plant was estimated to produce 170 g of “marketable substance.” The value of the Canadian crop is uncertain, but has been estimated to be in the billions of dollars annually (Heading 1998; MacLeod 1999).
Dehulled (i.e. hulled) hemp seed is a very recent phenomenon, first produced in quantity in Europe. Hemp seeds have been used as food since ancient times, but generally the whole seed, including the hull, was eaten. Hemp seed was a grain used in ancient China, although there has been only minor direct use of hemp seed as food by humans. In the past, hemp seed has generally been a food of the lower classes, or a famine food. Peanut-butter type preparations have been produced from hemp seed in Europe for centuries, but were rather gritty since technology for removing the hulls was rudimentary. Modern seed dehulling using mechanical separation produces a smooth, white, gritless hemp seed meal that needs no additional treatment before it is consumed. It is important to understand, therefore, that the quality of modern hemp seed for human consumption far exceeds anything produced historically. This seed meal should be distinguished from the protein-rich, oil-poor seed cake remaining after oil has been expressed, that is used for livestock feed. The seed cake is also referred to as “seed meal,” and has proven to be excellent for animals (Mustafa et al. 1999).
The first step to finding your correct CBD dosage is getting as much information as you can about the product you’re using. What is the concentration of CBD? Are there third-party lab tests that can confirm that? The CBD industry is still mainly a grassroots therapeutic movement, and as such, largely unregulated. Concentration and purity levels can differ greatly depending on the manufacturing process.
Hemp has the ability to mitigate the toxin transfer from contaminated soil into food products. This process uses phytoremediation, an organic process where toxins are absorbed by plant roots and then stored in the cellulose for disposal. Hemp phytoremediation became more well-known after the Chernobyl disaster for its use in helping grow crops that are safe for consumption.
There are ways to strain dangerous contaminants out of raw hemp paste. And most companies stand behind their quality and safety procedures. “We continuously test all our products ... to ensure our consumers get the levels of natural constituents they expect from the quality hemp stalk oil they purchase,” HempMedsPx states on its web site. “Additionally, all our products are tested for safety, to ensure there are no solvents, heavy metals, or other potentially harmful materials in our oil. Because we take these steps, we are always confident in our products, and you can be too.”